Skip to main content

DRUG

Stock
Health Care
Biotechnology

Performance overview

DRUG Price
Price Chart

Forward-looking statistics

Beta
0.56
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Company info

SectorHealth Care
IndustryBiotechnology
Employees—
Market cap$5.0M

Fundamentals

Enterprise value$95.1M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity0.30

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.40
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$4M
Put-call ratio—

Macro factor sensitivity

Growth+1.0
Credit+1.1
Liquidity-0.8
Inflation+1.2
Commodities-0.2
Interest Rates-3.6

Valuation

Dividend yield0.00%
PEG Ratio-0.00
Price to sales—
P/E Ratio-6.04
Enterprise Value to Revenue—
Price to book3.60

Upcoming events

Next earnings dayDecember 29, 2021
Next dividend day—
Ex. dividend day—

News

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

Chardan Research initiated coverage on Wednesday of Bright Minds Biosciences Inc. DRUG, an epilepsy drug developer.

Benzinga (May 7, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free